Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Greenwich Lifesciences Inc(GLSI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GLSI
11/06/2026: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Greenwich Lifesciences Inc is a clinical-stage biotechnology company focused exclusively on developing GP2, an immunotherapy intended to prevent breast cancer recurrence. The company has a lean structure that prioritizes R&D, though it remains pre-revenue and highly dependent on equity financing. The primary investment story rests on the potential success of its late-stage clinical trials. Key risks include the binary nature of clinical outcomes, significant competition from large pharmaceutical incumbents, and valuation uncertainty as a pre-profit firm. It is best suited for high-risk, long-term investors who can tolerate substantial volatility while monitoring clinical trial milestones and regulatory updates for definitive progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The speculative nature of clinical-stage biotech offers high growth potential contingent on binary trial outcomes. |
| Momentum investor | Mixed fit | Momentum here is highly conditional on clinical data releases and news-driven volatility. |
| Value investor | Weak fit | Traditional value metrics like P/E ratios are not applicable as the company is pre-revenue and pre-profit. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive research. |
| Low-risk investor | Weak fit | High clinical and regulatory risk makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price reacts sharply to clinical trial updates and regulatory news. |
| Valuation risk | High | Valuations are based on future potential rather than current fundamentals, carrying significant downside if trials fail. |
| Competition risk (Oncology drug development) | High | Large pharmaceutical competitors have deeper pockets and existing market dominance in breast cancer treatments. |
| Business quality | Medium | The company relies on a single-asset pipeline, which is inherently riskier than diversified biotech firms. |
| Dividend income | Low / none | The company is not profitable and does not generate income for shareholders. |
| Execution risk | High | Success depends entirely on the complex and uncertain process of clinical trial execution and FDA approval. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 9% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 222.67M USD | Price to earnings Ratio - | 1Y Target Price 57 |
Price to earnings Ratio - | 1Y Target Price 57 | ||
Volume (30-day avg) 131.5K shares | Beta 1.55 | 52 Weeks Range 7.78 - 34.10 | Updated Date 11/07/2026 |
52 Weeks Range 7.78 - 34.10 | Updated Date 11/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and clinical trial management for the GP2 immunotherapy candidate. | The company currently makes no money; it is burning cash to develop a potential medicine. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 206.16M | Price to Sales(TTM) - |
Enterprise Value 206.16M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 14.68M | Shares Floating 7.65M |
Shares Outstanding 14.68M | Shares Floating 7.65M | ||
Percent Insiders 47.91 | Percent Institutions 12.35 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.